Hormone Therapy, Chemotherapy, and Antibody Treatment in Breast Cancer – Effects on Tumour Cells in the Blood

How do different breast cancer treatments affect circulating tumour cells (CTCs) in the bloodstream, and what can changes in these cells tell us about treatment response?

Join this specialist online webinar on Tuesday 13 October 2026 for an exploration of how different systemic treatment approaches—including hormone therapy, chemotherapy and antibody-based treatments—can influence the number, viability and dynamics of living tumour cells circulating in the blood.

While treatment response is routinely assessed using a range of clinical and imaging measures, monitoring circulating tumour cells can provide additional information that may be relevant when considering treatment response, potential resistance and persistent tumour cell populations.

The webinar will use concrete clinical questions and examples to demonstrate how maintrac® and stemtrac® can be used to assess changes in living tumour cells during treatment. The session will also highlight current breast cancer-specific findings from ongoing research.

Topics will include:

• The effects of hormone therapy, chemotherapy and antibody-based treatments on circulating tumour cells
• Changes in the number and viability of living tumour cells in the bloodstream
• Understanding the dynamics of circulating tumour cells during treatment
• How monitoring may contribute to the assessment of treatment response
• Identifying patterns that may raise questions around treatment resistance or persistent tumour cell populations
• Clinical examples demonstrating the use of maintrac® and stemtrac®
• Current research findings relating specifically to breast cancer

This webinar will be particularly relevant to oncologists, healthcare professionals involved in breast cancer care, laboratory specialists and practitioners interested in circulating tumour cell monitoring and personalised approaches to treatment assessment.